keyword
MENU ▼
Read by QxMD icon Read
search

Allogenic HSCT

keyword
https://www.readbyqxmd.com/read/29910804/targeting-inflammatory-t-helper-cells-via-retinoic-acid-related-orphan-receptor-gamma-t-is-ineffective-to-prevent-allo-response-driven-colitis
#1
Vera Buchele, Benjamin Abendroth, Maike Büttner-Herold, Tina Vogler, Johanna Rothamer, Sakhila Ghimire, Evelyn Ullrich, Ernst Holler, Markus F Neurath, Kai Hildner
Intestinal graft-versus-host disease (GvHD) is a life-threatening, inflammatory donor T cell-mediated complication of allogeneic hematopoietic stem cell transplantation (allo-HSCT). In the light of the reported efficacy of interleukin-23 (IL-23)-blockade to mitigate syngeneic intestinal inflammation in inflammatory bowel disease patients, targeting IL-23 and thereby interleukin-17a (IL-17a) producing T helper (Th17) cells as the T cell subset assumed to be mostly regulated by IL-23, has emerged as a putatively general concept to harness immune-mediated mucosal inflammation irrespective of the underlying trigger...
2018: Frontiers in Immunology
https://www.readbyqxmd.com/read/29910468/enhanced-expressions-of-fhl2-and-iaspp-predict-poor-prognosis-in-acute-myeloid-leukemia
#2
Zhiheng Cheng, Yifeng Dai, Yifan Pang, Yang Jiao, Hongmian Zhao, Zhihui Zhang, Tong Qin, Ning Hu, Yijie Zhang, Xiaoyan Ke, Yang Chen, Depei Wu, Jinlong Shi, Lin Fu
iASPP is a negative regulator of the apoptotic function of p53, and it can enhance the ability of hematopoietic stem cells to self-renew and resist chemo- and radiation therapy. Recent study showed that iASPP could impact the proliferation and apoptosis of leukemia cells by interacting with FHL2. However, whether they have prognostic significance in acute myeloid leukemia (AML) is unknown. Eighty-four AML patients with FHL2 and iASPP expression data from The Cancer Genome Atlas database were enrolled in the study...
June 18, 2018: Cancer Gene Therapy
https://www.readbyqxmd.com/read/29909153/gastrointestinal-graft-versus-host-disease-is-a-risk-factor-for-post-engraftment-blood-stream-infection-in-allogeneic-hematopoietic-stem-cell-transplant-recipients
#3
Yasuo Mori, Goichi Yoshimoto, Ruriko Nishida, Takeshi Sugio, Kohta Miyawaki, Takahiro Shima, Yoji Nagasaki, Noriko Miyake, Yukiko Harada, Yuya Kunisaki, Kenjiro Kamezaki, Akihiko Numata, Koji Kato, Motoaki Shiratsuchi, Takahiro Maeda, Katsuto Takenaka, Hiromi Iwasaki, Nobuyuki Shimono, Koichi Akashi, Toshihiro Miyamoto
Bloodstream infection (BSI) is a well-known cause of morbidity and mortality in allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients. Here, we conducted a retrospective study to assess the morbidity, etiology, risk factors, and outcomes of BSI in the post-engraftment period (PE-BSI) following allo-HSCT. Forty-three out of 316 patients (13.6%) developed 57 PE-BSI episodes, in which 62 pathogens were isolated: gram-positive bacteria, gram-negative bacteria, and fungi, respectively, accounted for 54...
June 14, 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29909151/hematogones-predict-better-outcome-in-allogeneic-hematopoietic-stem-cell-transplantation-irrespective-of-graft-sources
#4
Takashi Ishio, Junichi Sugita, Takahiro Tateno, Daisuke Hidaka, Eiko Hayase, Souichi Shiratori, Kohei Okada, Hideki Goto, Masahiro Onozawa, Masao Nakagawa, Daigo Hashimoto, Kaoru Kahata, Katsuya Fujimoto, Tomoyuki Endo, Takeshi Kondo, Takanori Teshima
Benign precursors of B lymphocytes, termed hematogones, are observed in the regenerative state of hematopoiesis following chemotherapy or allogeneic hematopoietic stem cell transplantation (allo-HSCT). Previous studies have demonstrated that expansion of hematogones correlates with better clinical outcomes after allo-HSCT. We retrospectively analyzed the association between hematogones and clinical outcomes in 309 consecutive patients undergone allo-HSCT, which was the largest population-based cohort reported so far...
June 14, 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29904089/mutational-spectrum-and-prognostic-stratification-of-intermediate-risk-acute-myeloid-leukemia
#5
Sun Wu, Yifeng Dai, Yuan Zhang, Xiufeng Wang, Lihua Wang, Dong Ma, Lingxiu Zhang, Yifan Pang, Yang Jiao, Mingshan Niu, Kailin Xu, Xiaoyan Ke, Jinlong Shi, Zhiheng Cheng, Lin Fu
The mutational spectrum and prognostic stratification of intermediate-risk acute myeloid leukemia (IR-AML), which accounts for a substantial number of AML, are unclear. In order to explore the prognostic significance of the mutational spectrum in IR-AML, 106 IR-AML patients were collected from The Cancer Genome Atlas database. Sixty-two patients underwent chemotherapy-only, forty-four proceeded to allogeneic hematopoietic stem cell transplantation (allo-HSCT). Fifty-five patients had more than five recurrent genetic mutations...
June 15, 2018: Cancer Gene Therapy
https://www.readbyqxmd.com/read/29901213/pbpk-modeling-strategy-for-predicting-complex-drug-interactions-of-letermovir-as-a-perpetrator-in-support-of-product-labeling
#6
Ying-Hong Wang, Dapeng Chen, Georgy Hartmann, Carolyn R Cho, Karsten Menzel
Letermovir is a human cytomegalovirus (CMV) terminase inhibitor for the prophylaxis of CMV infection in allogeneic hematopoietic stem-cell transplant (HSCT) recipients. In vitro, letermovir is a time-dependent inhibitor and an inducer of cytochrome P450 (CYP)3A, and an inhibitor of CYP2C8 and organic anion transporting polypeptide (OATP)1B. A stepwise approach was taken to qualify the interaction model of an existing letermovir physiologically-based pharmacokinetic (PBPK) model to predict letermovir interactions with CYP3A and OATP1B...
June 14, 2018: Clinical Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/29899574/pre-engraftment-cytomegalovirus-dnaemia-in-allogeneic-hematopoietic-stem-cell-transplant-recipients-incidence-risk-factors-and-clinical-outcomes
#7
Carlos Solano, Estela Giménez, Eliseo Albert, Eva María Mateo, Montserrat Gómez, Rosa Goterris, Ariadna Pérez, Paula Amat, Juan Carlos Hernández-Boluda, Marc Poch, José Luis Piñana, David Navarro
To gauge the risk of delaying initiation of prophylaxis with letermovir from the time of donor infusion to prevent CMV infection in allo-HSCT recipients we investigated the clinical outcomes of CMV DNAemia episodes occurring before engraftment, and compared to that of episodes developing after engraftment (up to day +365). A total of 197 consecutive adult patients were included. Plasma CMV DNA load was monitored by real-time PCR assays [limit of detection: 31 IU/ml]. A total of 150 out of 197 patients had CMV DNAemia (cumulative incidence of 77%; 95% CI, 73-81%), and 38 out of the 197 patients developed it before engraftment (cumulative incidence, 19%; 95% CI, 10-30...
June 13, 2018: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/29899572/hematopoietic-stem-cell-transplantation-for-isolated-extramedullary-relapse-of-acute-lymphoblastic-leukemia-in-children
#8
Maria Gabelli, Marco Zecca, Chiara Messina, Elisa Carraro, Barbara Buldini, Attilio Maria Rovelli, Franca Fagioli, Alice Bertaina, Edoardo Lanino, Claudio Favre, Marco Rabusin, Arcangelo Prete, Mimmo Ripaldi, Walter Barberi, Fulvio Porta, Maurizio Caniglia, Stella Santarone, Paolo D'Angelo, Giuseppe Basso, Franco Locatelli
Relapse of acute lymphoblastic leukemia (ALL) may occur in extramedullary sites, mainly central nervous system (CNS) and testis. Optimal post-remissional treatment for isolated extramedullary relapse (IEMR) is still controversial. We collected data of children treated with hematopoietic stem cell transplantation (HSCT) for ALL IEMR from 1990 to 2015 in Italy. Among 281 patients, 167 had a relapse confined to CNS, 73 to testis, 14 to mediastinum, and 27 to other organs. Ninety-seven patients underwent autologous HSCT, 79 received allogeneic HSCT from a matched family donor, 75 from a matched unrelated donor, and 30 from an HLA-haploidentical donor...
June 13, 2018: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/29894730/utility-of-autopsy-among-pediatric-allogeneic-hematopoietic-stem-cell-transplant-recipients-one-last-chance-to-learn
#9
Matthew S Kelly, Lisa Spees, Richard Vinesett, Andre Stokhuyzen, Lauren McGill, Alan D Proia, Kirsten Jenkins, Mehreen Arshad, Patrick C Seed, Paul L Martin
BACKGROUND: Autopsy may confirm clinical diagnoses or identify conditions that were not suspected prior to a patient's death. Previous studies evaluating the utility of autopsy in hematopoietic stem cell transplant (HSCT) recipients yielded conflicting results. METHODS: We conducted a retrospective cohort study of children (<18 years of age) undergoing allogeneic HSCT at Duke University who died of any cause between January 1, 1995 and December 31, 2016. We evaluated associations between patient characteristics and autopsy performance using Chi-square or Fisher's exact tests...
June 9, 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29893798/a-randomized-placebo-controlled-trial-of-fidaxomicin-for-prophylaxis-of-clostridium-difficile-associated-diarrhea-in-adults-undergoing-hematopoietic-stem-cell-transplantation
#10
Kathleen M Mullane, Drew J Winston, Ajay Nooka, Michele I Morris, Patrick Stiff, Michael J Dugan, Henry Holland, Kevin Gregg, Javier A Adachi, Steven A Pergam, Barbara D Alexander, Erik R Dubberke, Natalya Broyde, Sherwood L Gorbach, Pamela S Sears
Background: Clostridium difficile-associated diarrhea (CDAD) is common during hematopoietic stem-cell transplantation (HSCT) and is associated with increased morbidity and mortality. We evaluated fidaxomicin for prevention of CDAD in HSCT patients. Methods: In this double-blind study, subjects undergoing HSCT with fluoroquinolone prophylaxis stratified by transplant type (autologous/allogeneic) were randomized to once-daily oral fidaxomicin 200mg or matching placebo...
June 9, 2018: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/29893458/low-dose-azacitidine-maintenance-therapy-after-allogeneic-stem-cell-transplantation-for-high-risk-pediatric-acute-myeloid-leukemia
#11
Akihiro Tamura, Toshiaki Ishida, Atsuro Saito, Nobuyuki Yamamoto, Takehito Yokoi, Suguru Uemura, Nanako Nino, Takahiro Fujiwara, Teppei Tahara, Sayaka Nakamura, Aiko Kozaki, Kenji Kishimoto, Daiichiro Hasegawa, Yoshiyuki Kosaka
The dismal prognosis of pediatric acute myeloid leukemia (AML) relapsing after hematopoietic stem cell transplantation (HSCT) requires exploration of novel strategies to prevent relapse. Azacitidine (AZA) maintenance therapy could potentially reduce the recurrence rate post HSCT. Here, we presents the cases of three children with high-risk AML post HSCT who were treated with low-dose AZA maintenance therapy, demonstrating the feasibility of this therapy. Currently, all three are in complete remission for 13-41 months despite their high-risk characteristics...
June 12, 2018: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/29891441/adverse-events-associated-with-infusion-of-hematopoietic-stem-cell-products-a-prospective-and-multicenter-surveillance-study
#12
REVIEW
Kazuhiko Ikeda, Hitoshi Ohto, Yoshiki Okuyama, Minami Yamada-Fujiwara, Heiwa Kanamori, Shin-Ichiro Fujiwara, Kazuo Muroi, Takehiko Mori, Kinuyo Kasama, Tohru Iseki, Tokiko Nagamura-Inoue, Nobuharu Fujii, Takashi Ashida, Kazuaki Kameda, Junya Kanda, Asao Hirose, Tsutomu Takahashi, Kazuhiro Nagai, Keiji Minakawa, Ryuji Tanosaki
Adverse events (AEs) associated with blood transfusions, including component-specific red cell, platelet, and plasma products, have been extensively surveyed. In contrast, surveillance of AEs associated with hematopoietic stem cell (HSC) products in HSC transplantation (HSCT) has been less rigorous, even though HSC products include a diversity of immature and mature hematopoietic cells, substantial plasma, and dimethyl sulfoxide (DMSO) in the case of cryopreserved HSC products. HSC infusion-related AEs have been attributed to DMSO toxicity, but AEs associated with the infusion of noncryopreserved HSC products are not uncommon...
June 1, 2018: Transfusion Medicine Reviews
https://www.readbyqxmd.com/read/29885009/successful-induction-of-therapeutic-urinary-concentration-by-intravenous-ganciclovir-and-oral-valganciclovir-with-remission-of-adenoviral-hemorrhagic-cystitis-after-cord-blood-transplantation
#13
Toshimitsu Yanagisawa, Shoji Saito, Yoshihiko Katsuyama, Koichi Hirabayashi, Tomonari Shigemura, Miyuki Tanaka, Kazuo Sakashita, Yozo Nakazawa
AdV11-HC is one of the major complications after allogeneic HSCT in Japan. We previously reported that the intravenous infusion of ganciclovir was effective against AdV11-HC in a post-transplant patient. We here report a case of a 10-year-old boy who underwent cord blood transplantation for the treatment of relapsed lymphoblastic lymphoma. He developed AdV11-HC with an elevated AdV load in his urine and blood on day 14 after HSCT. He was immediately treated with intravenous ganciclovir; he rapidly achieved a remission of AdV11-HC with a decreased AdV load in his urine and blood...
June 8, 2018: Pediatric Transplantation
https://www.readbyqxmd.com/read/29884406/integrated-genomic-characterization-of-oral-carcinomas-in-post-hematopoietic-stem-cell-transplantation-survivors
#14
Glenn J Hanna, Eric R Kofman, Muhammad Ali Shazib, Sook-Bin Woo, Brendan Reardon, Nathaniel S Treister, Robert I Haddad, Corey S Cutler, Joseph H Antin, Eliezer M Van Allen, Ravindra Uppaluri, Robert J Soiffer
OBJECTIVES: Secondary oral squamous cell carcinoma (OSCC) is a late complication in allogeneic hematopoietic stem cell transplantation (HSCT) patients, but little is known about long-term outcomes and prognostication. Additionally, molecular alterations and immunologic insights unique to this disease remain largely unexplored. METHODS: We present a cohort of 31 patients with post-HSCT OSCC and reported on clinicopathologic predictors of survival. Whole-exome sequencing was performed on 6 (19%) matched pairs of peripheral blood (post-conditioning, pre-HSCT) and tumor samples...
June 2018: Oral Oncology
https://www.readbyqxmd.com/read/29883599/impact-of-fluoroquinolone-prophylaxis-during-neutropenia-on-bloodstream-infection-data-from-a-surveillance-program-in-8-755-patients-receiving-high-dose-chemotherapy-for-haematologic-malignancies-between-2009-and-2014
#15
Winfried V Kern, Susanne Weber, Markus Dettenkofer, Klaus Kaier, Hartmut Bertz, Michael Behnke, Maja Weisser, Tim Götting, Andreas F Widmer, Christian Theilacker
OBJECTIVES: Antibacterial chemoprophylaxis with fluoroquinolones (FQPx) has been commonly used in cancer patients with neutropenia, but its efficacy has been challenged by the emergence of fluoroquinolone resistance. METHODS: The impact of FQPx on bloodstream infections (BSI) during neutropenia after high-dose chemotherapy for haematologic malignancies was evaluated through a multicenter hospital infection surveillance system for the period 2009 to 2014. RESULTS: Among 8,755 patients (4,223 allogeneic [allo-] HSCT, 3602 autologous [auto-] HSCT, 930 high-dose chemotherapy for acute leukemia [HDC]), 5,302 (61%) had received FQPx...
June 5, 2018: Journal of Infection
https://www.readbyqxmd.com/read/29883237/stem-cell-transplantation-in-sickle-cell-disease-therapeutic-potential-and-challenges-faced
#16
Alexis Leonard, John Tisdale
Sickle cell disease (SCD) is the most common inherited hemoglobinopathy worldwide, and is a life limiting disease with limited therapeutic options to reduce disease severity. Despite being a monogenic disorder, the clinical phenotypes of SCD are variable, with few reliable predictors of disease severity easily identifying patients where the benefits of curative therapy outweigh the risks. Allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative option, though significant advances in gene therapy raise the promise for additional curative methods...
June 8, 2018: Expert Review of Hematology
https://www.readbyqxmd.com/read/29882232/utility-of-tissue-elafin-as-an-immunohistochemical-marker-for-diagnosis-of-acute-skin-graft-versus-host-disease-a-pilot-study
#17
G D Mahabal, L George, D Peter, M Bindra, M Thomas, A Srivastava, V Mathews, B George, S A Pulimood
BACKGROUND: The skin is the most common organ involved in acute graft-versus-host disease (GvHD). Because histopathology has limited utility in ruling out clinical mimics of acute skin GvHD, more accurate diagnostic techniques are required. AIM: To evaluate the utility of elafin expression in skin by immunohistochemistry (IHC) for accurate diagnosis of acute skin GvHD. METHODS: Consecutive allogeneic haematopoietic stem cell transplant (HSCT) recipients during a 6-month period who developed rash within the first 100 days post-transplant were recruited...
June 7, 2018: Clinical and Experimental Dermatology
https://www.readbyqxmd.com/read/29880247/development-and-current-use-of-in-hematopoietic-stem-cell-transplantation-in-children-and-adolescents-in-poland-report-of-the-polish-pediatric-study-group-for-hematopoietic-stem-cell-transplantation-of-the-polish-society-for-pediatric-oncology-and-hematology
#18
REVIEW
Jacek Wachowiak, Alicja Chybicka, Jerzy R Kowalczyk, Mariusz Wysocki, Jolanta Goździk, Ewa Gorczyńska, Krzysztof Kałwak, Jan Styczyński, Katarzyna Drabko, Anna Pieczonka
The purpose of the survey was to evaluate the development and current use of hematopoietic stem cell transplantation (HSCT) in Poland between 1989-2016. The data for analysis (indication, number of performed HSCT, HSCT type, donor type, and stem cell source, year) have been collected annually using a standardized form. In Poland, between 1989-2016, the number of pediatric transplant beds grew from one to 40 and number and rate of transplants increased annually from 1/year (0.8/10 million) to 186/year (248/10 million)...
May 16, 2018: Transfusion and Apheresis Science
https://www.readbyqxmd.com/read/29877247/-molecular-targeted-therapy-and-its-impact-on-post-transplant-immunity
#19
Koji Kato
Over the past few decades, the advancements in the area of molecular-targeted therapy have revolutionized the treatment of hematological malignancies, thereby altering the role of allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, allo-HSCT continues to play an essential role in the treatment of hematological malignancies because the cure is rare by targeted therapy alone. In the modern era, the incorporation of molecular-targeted therapy, including chemotherapy and allo-HSCT, into the conventional therapy is the key to attaining therapeutic success...
2018: [Rinshō Ketsueki] the Japanese Journal of Clinical Hematology
https://www.readbyqxmd.com/read/29872594/management-of-recurrent-clostridium-difficile-infection-during-intensive-chemotherapy-and-stem-cell-transplantation-for-leukemia-case-with-literature-review
#20
Umar Zahid, Fnu Sagar, Mayar Al Mohajer, Aneela Majeed
Immunocompromised patients undergoing chemotherapy for hematologic malignancy and hematopoietic stem cell transplant (HSCT) recipients are at increased risk of Clostridium difficile (C. difficile) infection (CDI). The recurrence of infection and its associated morbidity and mortality are due to multiple risk factors. Diarrhea is common in HSCT recipients, but the diagnosis of diarrhea caused by CDI is a therapeutic challenge due to frequent Clostridium difficile colonization with diarrhea secondary to non-infectious causes...
April 2, 2018: Curēus
keyword
keyword
50968
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"